Evidence map›Paper›PMID 39190789›Full record

ArticleThe European respiratory journal2024

CD94

Tasha Tsao, Longhui Qiu, Reena Bharti, Avishai Shemesh, Alberto M Hernandez, Simon J Cleary, Nancy Y Greenland, Jesse Santos, Ruoshi Shi, Lu Bai and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Persistent and progressive acute lung allograft dysfunction is linked to cell compositional and transcriptional changes in small airways.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Tasha TsaoDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-1183-8912
Longhui QiuDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Reena BhartiDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Avishai ShemeshDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Alberto M HernandezParker Institute for Cancer Immunotherapy San Francisco, San Francisco, CA, USA.
Simon J ClearyInstitute of Pharmaceutical Science, King's College London, London, UK.ORCID https://orcid.org/0000-0001-5573-6363
Nancy Y GreenlandDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
Jesse SantosDepartment of Surgery, University of California San Francisco - East Bay, Oakland, CA, USA.
Ruoshi ShiDren Bio, Foster City, CA, USA.
Lu BaiDren Bio, Foster City, CA, USA.
Jennifer RichardsonDren Bio, Foster City, CA, USA.
Kimberley DilleyDren Bio, Foster City, CA, USA.
Matthias WillDren Bio, Foster City, CA, USA.
Nenad TomasevicDren Bio, Foster City, CA, USA.
Tereza SputovaDren Bio, Foster City, CA, USA.
Adam SallesDren Bio, Foster City, CA, USA.
Jeffrey KangDren Bio, Foster City, CA, USA.
Dongliang ZhangDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Steven R HaysDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-2887-8451
Jasleen KukrejaDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.
Jonathan P SingerDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0003-0224-7472
Lewis L LanierParker Institute for Cancer Immunotherapy San Francisco, San Francisco, CA, USA.
Mark R LooneyDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0003-0241-9190
John R GreenlandDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0003-1422-8367
Daniel R CalabreseDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA daniel.calabrese@ucsf.edu.ORCID https://orcid.org/0000-0002-0596-3434

Funding

Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
NK MemoryR01AI068129 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LANIER, LEWIS LEE · 2006 to 2020
$6.0M
Immunobiology of the normal and injured lungR35HL161241 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARK ROBERTS LOONEY · 2022 to 2026
$4.2M
Mechanisms and pathogenicity of SARS-CoV-2-induced neutrophil extracellular trapsR01AI160167 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LOONEY, MARK ROBERTS · 2021 to 2025
$3.1M
Innate Immune Mechanisms of Primary Graft Dysfunction after Lung TransplantationR01HL130324 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LOONEY, MARK ROBERTS · 2016 to 2019
$2.2M
Telomere Dysfunction as a cause of Chronic Lung Allograft DysfunctionR01HL151552 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GREENLAND, JOHN · 2020 to 2024
$1.6M
Cytek Aurora 5-Laser Spectral Flow CytometerS10OD026940 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SIMOES MARTINS BISPO, CLAUDIA · 2019 to 2019
$341k
BLRD VA IK2 BX005301CSRD VA I01 CX002011NHLBI NIH HHS R01 HL130324NHLBI NIH HHS R01 HL151552NHLBI NIH HHS R35 HL161241NIAID NIH HHS R01 AI068129NIAID NIH HHS R01 AI160167NIDDK NIH HHS P30 DK063720NIH HHS S10 OD026940
6 · The paper itself

Abstract

backgroundPulmonary ischaemia-reperfusion injury (IRI) is a major contributor to poor lung transplant outcomes. We recently demonstrated a central role of airway-centred natural killer (NK) cells in mediating IRI; however, there are no existing effective therapies for directly targeting NK cells in humans.

methodsWe hypothesised that a depleting anti-CD94 monoclonal antibody (mAb) would provide therapeutic benefit in mouse and human models of IRI based on high levels of

resultsWe found that CD94 is highly expressed on mouse and human NK cells, with increased expression during IRI. Anti-mouse and anti-human mAbs against CD94 showed effective NK cell depletion in mouse and human models and blunted lung damage and airway epithelial killing, respectively. In two different allogeneic orthotopic lung transplant mouse models, anti-CD94 treatment during induction reduced early lung injury and chronic inflammation relative to control therapies. Anti-CD94 did not increase donor antigen-presenting cells that could alter long-term graft acceptance.

conclusionsLung transplant induction regimens incorporating anti-CD94 treatment may safely improve early clinical outcomes.

Indexed as

Antibodies, MonoclonalKiller Cells, NaturalLung TransplantationMice, Inbred C57BLNK Cell Lectin-Like Receptor Subfamily DReperfusion InjuryAnimalsBronchoalveolar Lavage FluidDisease Models, AnimalFemaleHumansLungMaleMiceAntibodies, MonoclonalNK Cell Lectin-Like Receptor Subfamily D

Identifiers

PMID39190789
PMCPMC12128193

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.